- Zacks•14 days ago
The availability of the AR-V7 serves as a further development to Genomic Health's (GHDX) recently launched Oncotype SEQ Liquid Select, a next-generation, liquid biopsy test.
- The Wall Street Journal•16 days ago
Genomic Health has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional ...
Genomic Health Inc.NasdaqGS
After hours: 28.200.00 (0.00%) as of 5:01 PM EDT
|Bid||24.58 x 200|
|Ask||31.12 x 2000|
|52wk Range||20.05 - 35.79|
|Day's Range||28.04 - 29.00|
|Avg Vol (3m)||189,844|
As of 4:00 PM EDT. Market closed.